Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021
BackgroundUp-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions.AimWe estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign.MethodsWe conducted...
Gespeichert in:
| Veröffentlicht in: | Euro surveillance : bulletin européen sur les maladies transmissibles 2021-10, Vol.26 (43), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 43 |
| container_start_page | 1 |
| container_title | Euro surveillance : bulletin européen sur les maladies transmissibles |
| container_volume | 26 |
| creator | Stringhini, Silvia Zaballa, María-Eugenia Pullen, Nick Perez-Saez, Javier de Mestral, Carlos Loizeau, Andrea Jutta Lamour, Julien Pennacchio, Francesco Wisniak, Ania Dumont, Roxane Baysson, Hélène Richard, Viviane Lorthe, Elsa Semaani, Claire Balavoine, Jean-François Pittet, Didier Vuilleumier, Nicolas Chappuis, François Kherad, Omar Azman, Andrew S Posfay-Barbe, Klara Kaiser, Laurent Guessous, Idris |
| description | BackgroundUp-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions.AimWe estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign.MethodsWe conducted a population-based cross-sectional serosurvey between 1 June and 7 July 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins using the Roche Elecsys immunoassays. We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies).ResultsAmong 3,355 individuals (54.1% women; 20.8% aged |
| doi_str_mv | 10.2807/1560-7917.ES.2021.26.43.2100830 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8555371</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2593194195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-7044fa9eeddc321c0665abc0ff28a4b1b8eb6de0e357dd724f53f56ee11d87273</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS0EomXhKyBLHODQBP-NkwuoWm0LqBISAa6W40y6rhJ7cZJF5dZvjkOXVeHkseY3T_PmIfSakpyVRL2lsiCZqqjKN3XOCKM5K3LBc0YJKTl5hE6PxOMH9Ql6No43hAhOKvYUnXChKFdVdYruaohhF2FvevAWcOiw8ZPL6vMvdbYO3zP259-E1sGICzwEP21H7PwU8LQFvDfWOm8mFzy2ZtgZd-1TF1-CT5pnuP7ppl8Qe-PbM0zxp9kDTqMqVf0tXhw8R08604_w4vCu0LeLzdf1h-zq8-XH9flVZkVRTZkiQnSmAmhbyxm1pCikaSzpOlYa0dCmhKZogQCXqm0VE53knSwAKG1LxRRfoXf3uru5GaC14Kdoer2LbjDxVgfj9L8d77b6Oux1KaXk6V4r9OYgEMOPGcZJD2600CdvEOZRM1kRymihREJf_YfehDn6ZG-hOK0ErWSi3t9TNoZxjNAdl6FEL3HrJUC9BKg3tV6OpVmhBdeHuJPCy4eejvN_8-W_Aby4pvc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2593194195</pqid></control><display><type>article</type><title>Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Stringhini, Silvia ; Zaballa, María-Eugenia ; Pullen, Nick ; Perez-Saez, Javier ; de Mestral, Carlos ; Loizeau, Andrea Jutta ; Lamour, Julien ; Pennacchio, Francesco ; Wisniak, Ania ; Dumont, Roxane ; Baysson, Hélène ; Richard, Viviane ; Lorthe, Elsa ; Semaani, Claire ; Balavoine, Jean-François ; Pittet, Didier ; Vuilleumier, Nicolas ; Chappuis, François ; Kherad, Omar ; Azman, Andrew S ; Posfay-Barbe, Klara ; Kaiser, Laurent ; Guessous, Idris</creator><creatorcontrib>Stringhini, Silvia ; Zaballa, María-Eugenia ; Pullen, Nick ; Perez-Saez, Javier ; de Mestral, Carlos ; Loizeau, Andrea Jutta ; Lamour, Julien ; Pennacchio, Francesco ; Wisniak, Ania ; Dumont, Roxane ; Baysson, Hélène ; Richard, Viviane ; Lorthe, Elsa ; Semaani, Claire ; Balavoine, Jean-François ; Pittet, Didier ; Vuilleumier, Nicolas ; Chappuis, François ; Kherad, Omar ; Azman, Andrew S ; Posfay-Barbe, Klara ; Kaiser, Laurent ; Guessous, Idris ; Specchio-COVID19 study group ; on behalf of the Specchio-COVID19 study group</creatorcontrib><description>BackgroundUp-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions.AimWe estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign.MethodsWe conducted a population-based cross-sectional serosurvey between 1 June and 7 July 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins using the Roche Elecsys immunoassays. We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies).ResultsAmong 3,355 individuals (54.1% women; 20.8% aged < 18 years and 13.4% aged ≥ 65 years), 2,161 (64.4%) had anti-S antibodies and 906 (27.0%) had anti-N antibodies. The total seroprevalence was 66.1% (95% credible interval (CrI): 64.1-68.0). We estimated that 29.9% (95% Crl: 28.0-31.9) of the population developed antibodies after infection; the rest having developed antibodies via vaccination. Seroprevalence estimates differed markedly across age groups, being lowest among children aged 0-5 years (20.8%; 95% Crl: 15.5-26.7) and highest among older adults aged ≥ 75 years (93.1%; 95% Crl: 89.6-96.0). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with higher educational level.ConclusionMost of the population has developed anti-SARS-CoV-2 antibodies, despite most teenagers and children remaining vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and to minimise spread among children.</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>DOI: 10.2807/1560-7917.ES.2021.26.43.2100830</identifier><identifier>PMID: 34713799</identifier><language>eng</language><publisher>Sweden: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</publisher><subject>Adolescent ; Aged ; Antibodies ; Antibodies, Viral ; Child ; Child, Preschool ; COVID-19 ; COVID-19 vaccines ; Cross-Sectional Studies ; Female ; Humans ; Immunization ; Immunization Programs ; Infant ; Infant, Newborn ; Male ; Pandemics ; SARS-CoV-2 ; Seroepidemiologic Studies ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Switzerland</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2021-10, Vol.26 (43), p.1</ispartof><rights>Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Oct 28, 2021</rights><rights>This article is copyright of the authors or their affiliated institutions, 2021. 2021 The authors or their affiliated institutions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-7044fa9eeddc321c0665abc0ff28a4b1b8eb6de0e357dd724f53f56ee11d87273</citedby><cites>FETCH-LOGICAL-c469t-7044fa9eeddc321c0665abc0ff28a4b1b8eb6de0e357dd724f53f56ee11d87273</cites><orcidid>0000-0002-0237-882X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555371/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555371/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34713799$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stringhini, Silvia</creatorcontrib><creatorcontrib>Zaballa, María-Eugenia</creatorcontrib><creatorcontrib>Pullen, Nick</creatorcontrib><creatorcontrib>Perez-Saez, Javier</creatorcontrib><creatorcontrib>de Mestral, Carlos</creatorcontrib><creatorcontrib>Loizeau, Andrea Jutta</creatorcontrib><creatorcontrib>Lamour, Julien</creatorcontrib><creatorcontrib>Pennacchio, Francesco</creatorcontrib><creatorcontrib>Wisniak, Ania</creatorcontrib><creatorcontrib>Dumont, Roxane</creatorcontrib><creatorcontrib>Baysson, Hélène</creatorcontrib><creatorcontrib>Richard, Viviane</creatorcontrib><creatorcontrib>Lorthe, Elsa</creatorcontrib><creatorcontrib>Semaani, Claire</creatorcontrib><creatorcontrib>Balavoine, Jean-François</creatorcontrib><creatorcontrib>Pittet, Didier</creatorcontrib><creatorcontrib>Vuilleumier, Nicolas</creatorcontrib><creatorcontrib>Chappuis, François</creatorcontrib><creatorcontrib>Kherad, Omar</creatorcontrib><creatorcontrib>Azman, Andrew S</creatorcontrib><creatorcontrib>Posfay-Barbe, Klara</creatorcontrib><creatorcontrib>Kaiser, Laurent</creatorcontrib><creatorcontrib>Guessous, Idris</creatorcontrib><creatorcontrib>Specchio-COVID19 study group</creatorcontrib><creatorcontrib>on behalf of the Specchio-COVID19 study group</creatorcontrib><title>Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>BackgroundUp-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions.AimWe estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign.MethodsWe conducted a population-based cross-sectional serosurvey between 1 June and 7 July 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins using the Roche Elecsys immunoassays. We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies).ResultsAmong 3,355 individuals (54.1% women; 20.8% aged < 18 years and 13.4% aged ≥ 65 years), 2,161 (64.4%) had anti-S antibodies and 906 (27.0%) had anti-N antibodies. The total seroprevalence was 66.1% (95% credible interval (CrI): 64.1-68.0). We estimated that 29.9% (95% Crl: 28.0-31.9) of the population developed antibodies after infection; the rest having developed antibodies via vaccination. Seroprevalence estimates differed markedly across age groups, being lowest among children aged 0-5 years (20.8%; 95% Crl: 15.5-26.7) and highest among older adults aged ≥ 75 years (93.1%; 95% Crl: 89.6-96.0). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with higher educational level.ConclusionMost of the population has developed anti-SARS-CoV-2 antibodies, despite most teenagers and children remaining vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and to minimise spread among children.</description><subject>Adolescent</subject><subject>Aged</subject><subject>Antibodies</subject><subject>Antibodies, Viral</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Male</subject><subject>Pandemics</subject><subject>SARS-CoV-2</subject><subject>Seroepidemiologic Studies</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Switzerland</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9v1DAQxS0EomXhKyBLHODQBP-NkwuoWm0LqBISAa6W40y6rhJ7cZJF5dZvjkOXVeHkseY3T_PmIfSakpyVRL2lsiCZqqjKN3XOCKM5K3LBc0YJKTl5hE6PxOMH9Ql6No43hAhOKvYUnXChKFdVdYruaohhF2FvevAWcOiw8ZPL6vMvdbYO3zP259-E1sGICzwEP21H7PwU8LQFvDfWOm8mFzy2ZtgZd-1TF1-CT5pnuP7ppl8Qe-PbM0zxp9kDTqMqVf0tXhw8R08604_w4vCu0LeLzdf1h-zq8-XH9flVZkVRTZkiQnSmAmhbyxm1pCikaSzpOlYa0dCmhKZogQCXqm0VE53knSwAKG1LxRRfoXf3uru5GaC14Kdoer2LbjDxVgfj9L8d77b6Oux1KaXk6V4r9OYgEMOPGcZJD2600CdvEOZRM1kRymihREJf_YfehDn6ZG-hOK0ErWSi3t9TNoZxjNAdl6FEL3HrJUC9BKg3tV6OpVmhBdeHuJPCy4eejvN_8-W_Aby4pvc</recordid><startdate>20211028</startdate><enddate>20211028</enddate><creator>Stringhini, Silvia</creator><creator>Zaballa, María-Eugenia</creator><creator>Pullen, Nick</creator><creator>Perez-Saez, Javier</creator><creator>de Mestral, Carlos</creator><creator>Loizeau, Andrea Jutta</creator><creator>Lamour, Julien</creator><creator>Pennacchio, Francesco</creator><creator>Wisniak, Ania</creator><creator>Dumont, Roxane</creator><creator>Baysson, Hélène</creator><creator>Richard, Viviane</creator><creator>Lorthe, Elsa</creator><creator>Semaani, Claire</creator><creator>Balavoine, Jean-François</creator><creator>Pittet, Didier</creator><creator>Vuilleumier, Nicolas</creator><creator>Chappuis, François</creator><creator>Kherad, Omar</creator><creator>Azman, Andrew S</creator><creator>Posfay-Barbe, Klara</creator><creator>Kaiser, Laurent</creator><creator>Guessous, Idris</creator><general>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</general><general>European Centre for Disease Prevention and Control (ECDC)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0237-882X</orcidid></search><sort><creationdate>20211028</creationdate><title>Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021</title><author>Stringhini, Silvia ; Zaballa, María-Eugenia ; Pullen, Nick ; Perez-Saez, Javier ; de Mestral, Carlos ; Loizeau, Andrea Jutta ; Lamour, Julien ; Pennacchio, Francesco ; Wisniak, Ania ; Dumont, Roxane ; Baysson, Hélène ; Richard, Viviane ; Lorthe, Elsa ; Semaani, Claire ; Balavoine, Jean-François ; Pittet, Didier ; Vuilleumier, Nicolas ; Chappuis, François ; Kherad, Omar ; Azman, Andrew S ; Posfay-Barbe, Klara ; Kaiser, Laurent ; Guessous, Idris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-7044fa9eeddc321c0665abc0ff28a4b1b8eb6de0e357dd724f53f56ee11d87273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Aged</topic><topic>Antibodies</topic><topic>Antibodies, Viral</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Male</topic><topic>Pandemics</topic><topic>SARS-CoV-2</topic><topic>Seroepidemiologic Studies</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Switzerland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stringhini, Silvia</creatorcontrib><creatorcontrib>Zaballa, María-Eugenia</creatorcontrib><creatorcontrib>Pullen, Nick</creatorcontrib><creatorcontrib>Perez-Saez, Javier</creatorcontrib><creatorcontrib>de Mestral, Carlos</creatorcontrib><creatorcontrib>Loizeau, Andrea Jutta</creatorcontrib><creatorcontrib>Lamour, Julien</creatorcontrib><creatorcontrib>Pennacchio, Francesco</creatorcontrib><creatorcontrib>Wisniak, Ania</creatorcontrib><creatorcontrib>Dumont, Roxane</creatorcontrib><creatorcontrib>Baysson, Hélène</creatorcontrib><creatorcontrib>Richard, Viviane</creatorcontrib><creatorcontrib>Lorthe, Elsa</creatorcontrib><creatorcontrib>Semaani, Claire</creatorcontrib><creatorcontrib>Balavoine, Jean-François</creatorcontrib><creatorcontrib>Pittet, Didier</creatorcontrib><creatorcontrib>Vuilleumier, Nicolas</creatorcontrib><creatorcontrib>Chappuis, François</creatorcontrib><creatorcontrib>Kherad, Omar</creatorcontrib><creatorcontrib>Azman, Andrew S</creatorcontrib><creatorcontrib>Posfay-Barbe, Klara</creatorcontrib><creatorcontrib>Kaiser, Laurent</creatorcontrib><creatorcontrib>Guessous, Idris</creatorcontrib><creatorcontrib>Specchio-COVID19 study group</creatorcontrib><creatorcontrib>on behalf of the Specchio-COVID19 study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stringhini, Silvia</au><au>Zaballa, María-Eugenia</au><au>Pullen, Nick</au><au>Perez-Saez, Javier</au><au>de Mestral, Carlos</au><au>Loizeau, Andrea Jutta</au><au>Lamour, Julien</au><au>Pennacchio, Francesco</au><au>Wisniak, Ania</au><au>Dumont, Roxane</au><au>Baysson, Hélène</au><au>Richard, Viviane</au><au>Lorthe, Elsa</au><au>Semaani, Claire</au><au>Balavoine, Jean-François</au><au>Pittet, Didier</au><au>Vuilleumier, Nicolas</au><au>Chappuis, François</au><au>Kherad, Omar</au><au>Azman, Andrew S</au><au>Posfay-Barbe, Klara</au><au>Kaiser, Laurent</au><au>Guessous, Idris</au><aucorp>Specchio-COVID19 study group</aucorp><aucorp>on behalf of the Specchio-COVID19 study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2021-10-28</date><risdate>2021</risdate><volume>26</volume><issue>43</issue><spage>1</spage><pages>1-</pages><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><abstract>BackgroundUp-to-date seroprevalence estimates are critical to describe the SARS-CoV-2 immune landscape and to guide public health decisions.AimWe estimate seroprevalence of anti-SARS-CoV-2 antibodies 15 months into the COVID-19 pandemic and 6 months into the vaccination campaign.MethodsWe conducted a population-based cross-sectional serosurvey between 1 June and 7 July 2021, recruiting participants from age- and sex-stratified random samples of the general population. We tested participants for anti-SARS-CoV-2 antibodies targeting the spike (S) or nucleocapsid (N) proteins using the Roche Elecsys immunoassays. We estimated the anti-SARS-CoV-2 antibodies seroprevalence following vaccination and/or infection (anti-S antibodies), or infection only (anti-N antibodies).ResultsAmong 3,355 individuals (54.1% women; 20.8% aged < 18 years and 13.4% aged ≥ 65 years), 2,161 (64.4%) had anti-S antibodies and 906 (27.0%) had anti-N antibodies. The total seroprevalence was 66.1% (95% credible interval (CrI): 64.1-68.0). We estimated that 29.9% (95% Crl: 28.0-31.9) of the population developed antibodies after infection; the rest having developed antibodies via vaccination. Seroprevalence estimates differed markedly across age groups, being lowest among children aged 0-5 years (20.8%; 95% Crl: 15.5-26.7) and highest among older adults aged ≥ 75 years (93.1%; 95% Crl: 89.6-96.0). Seroprevalence of antibodies developed via infection and/or vaccination was higher among participants with higher educational level.ConclusionMost of the population has developed anti-SARS-CoV-2 antibodies, despite most teenagers and children remaining vulnerable to infection. As the SARS-CoV-2 Delta variant spreads and vaccination rates stagnate, efforts are needed to address vaccine hesitancy, particularly among younger individuals and to minimise spread among children.</abstract><cop>Sweden</cop><pub>Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)</pub><pmid>34713799</pmid><doi>10.2807/1560-7917.ES.2021.26.43.2100830</doi><orcidid>https://orcid.org/0000-0002-0237-882X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1560-7917 |
| ispartof | Euro surveillance : bulletin européen sur les maladies transmissibles, 2021-10, Vol.26 (43), p.1 |
| issn | 1560-7917 1025-496X 1560-7917 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8555371 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adolescent Aged Antibodies Antibodies, Viral Child Child, Preschool COVID-19 COVID-19 vaccines Cross-Sectional Studies Female Humans Immunization Immunization Programs Infant Infant, Newborn Male Pandemics SARS-CoV-2 Seroepidemiologic Studies Serology Severe acute respiratory syndrome coronavirus 2 Switzerland |
| title | Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A38%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seroprevalence%20of%20anti-SARS-CoV-2%20antibodies%206%20months%20into%20the%20vaccination%20campaign%20in%20Geneva,%20Switzerland,%201%20June%20to%207%20July%202021&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Stringhini,%20Silvia&rft.aucorp=Specchio-COVID19%20study%20group&rft.date=2021-10-28&rft.volume=26&rft.issue=43&rft.spage=1&rft.pages=1-&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/1560-7917.ES.2021.26.43.2100830&rft_dat=%3Cproquest_pubme%3E2593194195%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2593194195&rft_id=info:pmid/34713799&rfr_iscdi=true |